Frames reducing exposure as the high-reward move: sell into the $380–387 shelf at $385 with a stop at $393.18 (~4:1 to the $347–355 target), get down to 1–2% or zero, and use the liquidity from the Oct 2 pop to exit ahead of Q3 earnings.
Dismisses the technical recovery as a counter-trend bounce under a declining 200 SMA, with the July 115.6M-share crash the more important volume signal than the Oct 2 surge.
Agrees with trimming but rejects the aggressive analyst's 4:1 math as fill-dependent and the $393.18 stop as inside normal ATR noise (12.44); frames the risk/reward from $370.59 as roughly symmetric (~6% each way).
Proposes selling an initial tranche now near $370, a second into the $380–387 shelf if it appears, close-based (not intraday) invalidation at $347, and holding a residual 1–2% for optionality.
Supports the Sell as a risk-management trim to 1–2%, but opposes framing it as a high-conviction short — an $8 stop against a 12.44 ATR is "inside the daily noise," and a fresh short into binary Q3 earnings has negative optionality.
Wants an initial tranche sold now rather than waiting for $385, a small residual long preserved for robotaxi/AI optionality, and $347 (close-based) as the real invalidation line.
Thesis: TSLA at $370.59 shows present-tense fundamentals that all three risk voices independently accepted: Q2 2026 operating margin of 1.4% (operating income −57% YoY), gross margin down to 16.8% from 21.1%, H1 net income down roughly a third despite +25.5% revenue growth, diluted EPS falling $4.31 → $2.04 → $1.08 across 2023–2025, the first negative FCF quarter (−$1.1B on $5.8B capex, up 142% YoY for robotaxi/AI/Megapack), SBC of ~$3.8B roughly equal to TTM net income, and share count up ~22.5% YoY. At ~385x trailing earnings and ~14x sales there is no cushion for execution error. Q3 deliveries of 486,532 topped a lowered bar but fell ~2% YoY, with production below deliveries — inventory drawdown, not a demand breakout; the +4.65% move on 2x average volume is exit liquidity, not a reason to add. Technically, price sits 6.1% below the declining 200 SMA at $393.18 and has been rejected three times at $380–387; from $370.59, risk/reward is roughly symmetric (~6% up vs. ~4–6% down to $347–355), with a tail below $347 opening to $327 and the July low at $298. This is Underweight, not Sell, because the floor is real: record $103.6B TTM revenue (+25.5% YoY), ~$27.4B net cash, and $18.7B TTM operating cash flow — negative FCF is a choice, not a crisis.
Action: trim to roughly 1–2% of the book (vs. a standard 3–5% single-name slot) in tranches — an initial sale at market now rather than waiting for a $385 fill, with the remainder executed into the $380–387 strength shelf if offered. Do not initiate or add at ~$370; treat the $363–366 confluence as a hold level, not a buy level. Define residual risk tightly: stop below $355, and a decisive close below $347 exits the remainder (next references $327–330, then the July low at $298). A sustained multi-week close above $393.18 on strong volume is the regime-change signal to begin rebuilding toward neutral, and the Q3 earnings print (positive FCF, gross margin above 18–20%, YoY delivery growth, slower share-count growth) is the mandatory re-underwrite checkpoint. Flagged data gaps: Yahoo Finance and StockTwits sentiment feeds were unavailable this window (low confidence), and no forward consensus estimates were provided, so no valuation-derived price target is supportable.